thalidomide has been researched along with Hypophosphatemia in 3 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
Hypophosphatemia: A condition of an abnormally low level of PHOSPHATES in the blood.
Excerpt | Relevance | Reference |
---|---|---|
"Panobinostat 20 mg in combination with bortezomib, thalidomide, and dexamethasone is an efficacious and well tolerated regimen for patients with relapsed multiple myeloma." | 9.22 | Bortezomib, thalidomide, dexamethasone, and panobinostat for patients with relapsed multiple myeloma (MUK-six): a multicentre, open-label, phase 1/2 trial. ( Brown, SR; Cavenagh, J; Cook, G; Flanagan, L; Gregory, W; Hall, A; Kishore, B; Low, E; Oakervee, H; Popat, R; Streetly, M; Yong, K, 2016) |
"This phase 1/2 study in patients with newly diagnosed multiple myeloma (N = 53) assessed CRd--carfilzomib (20, 27, or 36 mg/m2, days 1, 2, 8, 9, 15, 16 and 1, 2, 15, 16 after cycle 8), lenalidomide (25 mg/d, days 1-21), and weekly dexamethasone (40/20 mg cycles 1-4/5+)--in 28-day cycles." | 9.16 | A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma. ( Ahmed, A; Al-Zoubi, A; Anderson, T; Couriel, D; Detweiler-Short, K; Durecki, DE; Dytfeld, D; Griffith, KA; Jagannath, S; Jakubowiak, AJ; Jobkar, T; Kaminski, M; Lebovic, D; McDonnell, K; Mietzel, M; Nordgren, B; Stockerl-Goldstein, K; Vesole, DH; Vij, R, 2012) |
"Panobinostat 20 mg in combination with bortezomib, thalidomide, and dexamethasone is an efficacious and well tolerated regimen for patients with relapsed multiple myeloma." | 5.22 | Bortezomib, thalidomide, dexamethasone, and panobinostat for patients with relapsed multiple myeloma (MUK-six): a multicentre, open-label, phase 1/2 trial. ( Brown, SR; Cavenagh, J; Cook, G; Flanagan, L; Gregory, W; Hall, A; Kishore, B; Low, E; Oakervee, H; Popat, R; Streetly, M; Yong, K, 2016) |
"This phase 1/2 study in patients with newly diagnosed multiple myeloma (N = 53) assessed CRd--carfilzomib (20, 27, or 36 mg/m2, days 1, 2, 8, 9, 15, 16 and 1, 2, 15, 16 after cycle 8), lenalidomide (25 mg/d, days 1-21), and weekly dexamethasone (40/20 mg cycles 1-4/5+)--in 28-day cycles." | 5.16 | A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma. ( Ahmed, A; Al-Zoubi, A; Anderson, T; Couriel, D; Detweiler-Short, K; Durecki, DE; Dytfeld, D; Griffith, KA; Jagannath, S; Jakubowiak, AJ; Jobkar, T; Kaminski, M; Lebovic, D; McDonnell, K; Mietzel, M; Nordgren, B; Stockerl-Goldstein, K; Vesole, DH; Vij, R, 2012) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (66.67) | 24.3611 |
2020's | 1 (33.33) | 2.80 |
Authors | Studies |
---|---|
Regidor, B | 1 |
Swift, R | 1 |
Eades, B | 1 |
Emamy-Sadr, M | 1 |
Tarhini, F | 1 |
Spektor, TM | 1 |
Berenson, JR | 1 |
Popat, R | 1 |
Brown, SR | 1 |
Flanagan, L | 1 |
Hall, A | 1 |
Gregory, W | 1 |
Kishore, B | 1 |
Streetly, M | 1 |
Oakervee, H | 1 |
Yong, K | 1 |
Cook, G | 1 |
Low, E | 1 |
Cavenagh, J | 1 |
Jakubowiak, AJ | 1 |
Dytfeld, D | 1 |
Griffith, KA | 1 |
Lebovic, D | 1 |
Vesole, DH | 1 |
Jagannath, S | 1 |
Al-Zoubi, A | 1 |
Anderson, T | 1 |
Nordgren, B | 1 |
Detweiler-Short, K | 1 |
Stockerl-Goldstein, K | 1 |
Ahmed, A | 1 |
Jobkar, T | 1 |
Durecki, DE | 1 |
McDonnell, K | 1 |
Mietzel, M | 1 |
Couriel, D | 1 |
Kaminski, M | 1 |
Vij, R | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
A Phase I/IIa Trial of VTD-panobinostat Treatment and Panobinostat Maintenance in Relapsed and Relapsed/Refractory Multiple Myeloma Patients[NCT02145715] | Phase 1/Phase 2 | 54 participants (Anticipated) | Interventional | 2013-01-31 | Active, not recruiting | ||
A Prospective, Multicenter, Single Arm, Phase II Clinical Trial of Clarithromycin, Lenalidomide and Dexamethasone (BiRd Regimen) in the Treatment of the First Relapsed Multiple Myeloma[NCT04063189] | Phase 2 | 100 participants (Anticipated) | Interventional | 2017-03-21 | Recruiting | ||
A Pilot Study on the Efficacy of Daratumumab in Multiple Myeloma (MM) Patients in >VGPR/MRD-positive by Next Generation Flow[NCT03992170] | Phase 2 | 50 participants (Anticipated) | Interventional | 2018-12-31 | Recruiting | ||
Multicenter, Open-label, Single-arm, Phase 1b/2 Study of the Safety and Efficacy of Combination Treatment w/ Carfilzomib, Lenalidomide (Revlimid®) and Dexamethasone (CRD) in Subjects w/ Newly Diagnosed, Previously Untreated Multiple Myeloma Requiring Syst[NCT01029054] | Phase 1/Phase 2 | 53 participants (Actual) | Interventional | 2009-09-30 | Completed | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
Determine the MTD of Carfilzomib when combined with Lenalidomide and Dexamethasone. The estimated time to determine the MTD is 6 months. (NCT01029054)
Timeframe: 6 Months
Intervention | mg/m^2 (Number) |
---|---|
Carfilzomib, Lenalidomide w/Dexamethasone | 36 |
"The Progression Free Survival (PFS) rate will be determined at 12 and 24 months post treatment.~Progressive Disease (PD) is defined as an increase of greater than or equal to 25% from lowest response level in serum M-component and/ or urine M-component and/ or the difference between involved or uninvolved SFLC levels and/ or bone marrow % plasma cells. PD may also be the development of new bone lesions or soft tissue plasmacytomas or the increase in size of existing lesions. PD may also be the development of hypercalcemia." (NCT01029054)
Timeframe: 12 Months and 24 Months Post Treatment
Intervention | percentage of patients (Number) | |
---|---|---|
Percentage of Patients Without Progression at 12 m | Percentage of Patients Without Progression at 24 m | |
Carfilzomib, Lenalidomide w/Dexamethasone | 97 | 92 |
"The percentage of patients that achieve at least a sCR (Stringent Complete Response), at least a VGPR (Very Good Partial Response) and at least a PR (Partial Response) will be determined.~sCR is defined as:~Negative immunofixation on the serum and urine and~Disappearance of any soft tissue plasmacytomas and~< 5% plasma cells in bone marrow and~Normal SFLC ratio and~Absence of clonal cells in bone marrow~VGPR is defined as:~Serum and urine M-protein detectable by immunofixation but not on electrophoresis or~≥ 90% reduction in serum M-component with urine M-component < 100 mg per 24 hours~PR is defined as:~≥ 50% reduction of serum M-protein and reduction in 24-hour urinary M-protein by ≥ 90% or to < 200 mg per 24 hours~If present at baseline, a ≥ 50% reduction in the size of soft tissue plasmacytomas is also required" (NCT01029054)
Timeframe: 4 Months After Treatment Start
Intervention | percentage of patients (Number) | ||
---|---|---|---|
% of patients that achieve at least a sCR | % of patients that achieve at least a VGPR | % of patients that achieve at least a PR | |
Carfilzomib, Lenalidomide w/Dexamethasone | 42 | 81 | 98 |
2 trials available for thalidomide and Hypophosphatemia
Article | Year |
---|---|
Bortezomib, thalidomide, dexamethasone, and panobinostat for patients with relapsed multiple myeloma (MUK-six): a multicentre, open-label, phase 1/2 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Constipation; Dexamethasone; Diarr | 2016 |
Bortezomib, thalidomide, dexamethasone, and panobinostat for patients with relapsed multiple myeloma (MUK-six): a multicentre, open-label, phase 1/2 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Constipation; Dexamethasone; Diarr | 2016 |
Bortezomib, thalidomide, dexamethasone, and panobinostat for patients with relapsed multiple myeloma (MUK-six): a multicentre, open-label, phase 1/2 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Constipation; Dexamethasone; Diarr | 2016 |
Bortezomib, thalidomide, dexamethasone, and panobinostat for patients with relapsed multiple myeloma (MUK-six): a multicentre, open-label, phase 1/2 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Constipation; Dexamethasone; Diarr | 2016 |
A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Combined Mod | 2012 |
A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Combined Mod | 2012 |
A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Combined Mod | 2012 |
A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Combined Mod | 2012 |
1 other study available for thalidomide and Hypophosphatemia
Article | Year |
---|---|
Frequent occurrence of hypophosphatemia among multiple myeloma patients treated with elotuzumab: a single clinic retrospective study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; | 2021 |